1.1K(top 1%)
papers
57.6K(top 0.1%)
citations
113(top 0.1%)
h-index
222(top 0.1%)
g-index
1.2K
all documents
62.0K
doc citations
4.7K
citing journals

Top Articles

#TitleJournalYearCitations
1Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature20144,342
2Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine20121,955
3Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialLancet Oncology, The20191,467
4Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncology, The20151,419
5Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA - Journal of the American Medical Association20141,386
6Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncology, The20151,269
7Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerNature Genetics20121,186
8Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialLancet Oncology, The20161,091
9Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent MechanismMolecular Biology of the Cell2001962
10Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyJournal of Clinical Oncology2019811
11TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology2010805
12Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung CancerScience Translational Medicine2010761
13Acquired resistance to TKIs in solid tumours: learning from lung cancerNature Reviews Clinical Oncology2014740
14Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology2003613
15Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor StudyJournal of the National Cancer Institute2010598
16Proteomic patterns of tumour subsets in non-small-cell lung cancerLancet, The2003597
17Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon CancerGastroenterology2010576
18HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature2018572
19Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistanceNature Communications2012567
20Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialLancet, The2016529
21A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupOncologist2020520
22Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceCell2015516
23COX-2: A Molecular Target for Colorectal Cancer PreventionJournal of Clinical Oncology2005497
24Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyJournal of Clinical Oncology2019494
25Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumJournal of Clinical Oncology2020481
26Interdependent SMAD and JNK Signaling in Transforming Growth Factor-β-mediated TranscriptionJournal of Biological Chemistry1999476
27First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersJournal of Clinical Oncology2019457
28Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology2001414
29Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapyNature Nanotechnology2019406
30Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyLancet Oncology, The2017402
31Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for ChemopreventionJournal of Clinical Oncology2005379
32Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology2015357
33Integrin β1 Signaling Is Necessary for Transforming Growth Factor-β Activation of p38MAPK and Epithelial PlasticityJournal of Biological Chemistry2001354
34Ibrutinib for chronic graft-versus-host disease after failure of prior therapyBlood2017352
35The Epidemiology of Renal Cell CarcinomaJournal of Urology2006349
36Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaJournal of Clinical Oncology2013335
37Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyLancet Oncology, The2017322
38The landscape of recombination in African AmericansNature2011319
39KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyLancet, The2021315
40Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δCancer Cell2004314
41EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung CancerJournal of Clinical Oncology2009313
42Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaAmerican Journal of Hematology2019305
43Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and ErlotinibJournal of Clinical Oncology2005298
44Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialLancet Oncology, The2016293
45First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 StudyJournal of Clinical Oncology2022283
46Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerCancer Research2005283
47Myocarditis in the Setting of Cancer TherapeuticsCirculation2019278
48Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 FamiliesJournal of Clinical Oncology2020270
49Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerProceedings of the National Academy of Sciences of the United States of America2009251
50A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous LeukemiaCancer Discovery2018250